OTCMKTS:CXRXF ADVANZ PHARMA (CXRXF) Stock Price, News & Analysis $17.06 0.00 (0.00%) As of 06/10/2021 Add Compare Share Share Stock Analysis Stock Analysis About ADVANZ PHARMA Stock (OTCMKTS:CXRXF) Get ADVANZ PHARMA alerts:Sign Up Key Stats Today's Range$17.06▼$17.0650-Day Range$17.06▼$17.0652-Week Range$2.13▼$18.00Volume39 shsAverage Volume11,851 shsMarket Capitalization$834.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ADVANZ PHARMA is a specialty pharmaceutical company focused on the development, acquisition, licensing and commercialization of complex medicines and established pharmaceutical products. The company serves patients in areas where treatment options may be limited, with an emphasis on specialty, hospital and rare-disease therapies. Its portfolio includes branded medicines, generic products and niche treatments across therapeutic categories such as neurology, gastroenterology, ophthalmology, allergy and critical care. ADVANZ PHARMA’s activities include regulatory support, supply-chain management and commercialization, allowing it to provide medicines to healthcare providers and patients without relying solely on new drug discovery. The company is headquartered in London and operates through international markets, with products distributed across Europe and other regions. ADVANZ PHARMA was formerly known as Concordia International and adopted its current name as part of a broader strategic repositioning toward specialty and complex pharmaceuticals.AI Generated. May Contain Errors. Read More Receive CXRXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADVANZ PHARMA and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CXRXF Stock News HeadlinesPHAT Phathom Pharmaceuticals, Inc.April 6, 2024 | seekingalpha.comDimerix receives $10.7 million upfront payment from Advanz PharmaNovember 7, 2023 | msn.comThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply. But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle.September 16 at 1:00 AM | Traders Agency (Ad)Applied Therapeutics adds 19% on partnership with Advanz Pharma for lead assetJanuary 4, 2023 | msn.comMADE in America Act is critical for the pharmaceutical industrySeptember 27, 2022 | dallasnews.comDPolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in EuropeAugust 5, 2022 | seekingalpha.comIntercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.July 1, 2022 | benzinga.comIntercept Pharma to sell ex-U.S. rights for Ocaliva to Advanz PharmaMay 5, 2022 | seekingalpha.comSee More Headlines CXRXF Stock Analysis - Frequently Asked Questions How have CXRXF shares performed this year? ADVANZ PHARMA's stock was trading at $17.06 at the beginning of 2026. Since then, CXRXF stock has increased by 0.0% and is now trading at $17.06. How do I buy shares of ADVANZ PHARMA? Shares of CXRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:CXRXF CIKN/A Webwww.concordiarx.com Phone44-20-8588-9100FaxN/AEmployees429Year Founded2006Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.86 million Net Margins-15.31% Pretax MarginN/A Return on EquityN/A Return on Assets-4.38% Debt Debt-to-Equity Ratio257.04 Current Ratio2.39 Quick Ratio1.61 Sales & Book Value Annual Sales$525.58 million Price / Sales1.59 Cash FlowN/A Price / Cash FlowN/A Book Value$0.16 per share Price / Book106.63Miscellaneous Outstanding Shares48,913,000Free FloatN/AMarket Cap$834.46 million OptionableNot Optionable BetaN/A Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:CXRXF) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADVANZ PHARMA Corp. Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ADVANZ PHARMA With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
